Vascular BioSciences announces Cooperative R&D Agreement with the United States Army Institute for Surgical Research to develop solutions for acute respiratory distress syndrome secondary to battlefie
February 18, 2006 (Press Release) --
San Diego, Calif., February 17, 2006 - Vascular BioSciences (www.vascularbiosciences.com) announces a Cooperative Research and Development Agreement with the United States Army Institute for Surgical Research (USAISR) to develop diagnostic and therapeutic solutions addressing acute respiratory distress syndrome secondary to battlefield trauma.
The agreement, signed by Vascular BioSciences CEO David Mann and USAISR commander, Colonel John Holcomb, M.D., focuses on increasing the in-hospital survival of Department of Defense personnel at risk for developing acute respiratory distress syndrome (ARDS) as a result of battlefield trauma.
"This agreement reflects our ongoing efforts to further expand our combat casualty care research, and is consistent with our mission to develop medical solutions for our injured soldiers," said Colonel John B. Holcomb, commander of the United States Army Institute for Surgical Research.
“We look forward to working with the USAISR to help save the lives of our nation's brave fighting men and women, and are proud to contribute to our country's military medical research efforts,” said David Mann, CEO of Vascular BioSciences. "We look forward to expanding our collaboration with the USAISR to include further initiatives for improving combat casualty care."
"The pathophysiology of ARDS secondary to battlefield trauma is poorly understood, and therapeutic options are limited," said Colonel Lee Cancio, M.D., co-principal investigator, recently returned from Iraq and chief of research at the U.S. Army’s Burn Unit. “The survival of injured soldiers could be improved if we could accurately predict and diagnose ARDS in our patients while there is still time for effective counter-measures. The goal of our collaborative research with Vascular BioSciences is to develop therapeutic as well as diagnostic solutions for ARDS."
ARDS is an enormous problem in civilian as well as military hospitals. According to the non-profit ARDS Foundation (www.ardsusa.org), over 150,000 cases were reported last year in the U.S. resulting in approximately 75,000 deaths. If the other causes of ARDS such as sepsis, severe sepsis, and multi-organ failure syndrome are combined with ARDS, then over 750,000 cases occur annually resulting in 215,000 deaths or 9.3% of annual deaths in the US.
About Vascular BioSciences:
Vascular BioSciences, a diversified biomedical company based in San Diego, California, develops solutions for vascular-based disease patients. Vascular BioSciences has developed the endoarterial biopsy catheter to percutaneously obtain biopsy samples from the inner layer of blood vessels. Endoarterial biopsies will better enable the study, diagnosis, monitoring, and treatment of vascular-based diseases.
Vascular BioSciences is dedicated to developing innovative technologies to detect and treat vascular-based diseases in order to enhance and prolong human life.
For more information contact:
Vascular BioSciences
David Mann, CEO
(858) 273-2744
www.vascularbiosciences.com
The U.S Government or the USAISR does not directly or indirectly endorse any product or service provided, or to be provided, by Vascular BioSciences, and this press release shall not in any way imply an endorsement of any such product or service.
The agreement, signed by Vascular BioSciences CEO David Mann and USAISR commander, Colonel John Holcomb, M.D., focuses on increasing the in-hospital survival of Department of Defense personnel at risk for developing acute respiratory distress syndrome (ARDS) as a result of battlefield trauma.
"This agreement reflects our ongoing efforts to further expand our combat casualty care research, and is consistent with our mission to develop medical solutions for our injured soldiers," said Colonel John B. Holcomb, commander of the United States Army Institute for Surgical Research.
“We look forward to working with the USAISR to help save the lives of our nation's brave fighting men and women, and are proud to contribute to our country's military medical research efforts,” said David Mann, CEO of Vascular BioSciences. "We look forward to expanding our collaboration with the USAISR to include further initiatives for improving combat casualty care."
"The pathophysiology of ARDS secondary to battlefield trauma is poorly understood, and therapeutic options are limited," said Colonel Lee Cancio, M.D., co-principal investigator, recently returned from Iraq and chief of research at the U.S. Army’s Burn Unit. “The survival of injured soldiers could be improved if we could accurately predict and diagnose ARDS in our patients while there is still time for effective counter-measures. The goal of our collaborative research with Vascular BioSciences is to develop therapeutic as well as diagnostic solutions for ARDS."
ARDS is an enormous problem in civilian as well as military hospitals. According to the non-profit ARDS Foundation (www.ardsusa.org), over 150,000 cases were reported last year in the U.S. resulting in approximately 75,000 deaths. If the other causes of ARDS such as sepsis, severe sepsis, and multi-organ failure syndrome are combined with ARDS, then over 750,000 cases occur annually resulting in 215,000 deaths or 9.3% of annual deaths in the US.
About Vascular BioSciences:
Vascular BioSciences, a diversified biomedical company based in San Diego, California, develops solutions for vascular-based disease patients. Vascular BioSciences has developed the endoarterial biopsy catheter to percutaneously obtain biopsy samples from the inner layer of blood vessels. Endoarterial biopsies will better enable the study, diagnosis, monitoring, and treatment of vascular-based diseases.
Vascular BioSciences is dedicated to developing innovative technologies to detect and treat vascular-based diseases in order to enhance and prolong human life.
For more information contact:
Vascular BioSciences
David Mann, CEO
(858) 273-2744
www.vascularbiosciences.com
The U.S Government or the USAISR does not directly or indirectly endorse any product or service provided, or to be provided, by Vascular BioSciences, and this press release shall not in any way imply an endorsement of any such product or service.
Email
Print
SPAM
